Linskey, M.E., Andrews, D.W., Asher, A.L., Burri, S.H., Kondziolka, D., Robinson, P.D., Ammirati, M., Cobbs, C.S., Gaspar, L.E., Loeffler, J.S., McDermott, M., Mehta, M.P., Mikkelsen, T., Olson, J.J., Paleologos, N.A., Patchell, R.A., Ryken, T.C. and Kalkanis, S.N. (2010) The Role of Stereotactic Radiosurgery in the Management of Patients with Newly Diagnosed Brain Metastases: A Systematic Review and Evidence-Based Clinical Practice Guideline. Journal of Neuro-Oncology, 96, 45-68.
http://dx.doi.org/10.1007/s11060-009-0073-4

has been cited by the following article:

• TITLE: Cardiac Radiosurgery for the Treatment of Atrial Fibrillation

  AUTHORS: Nikhilesh Bhatt, Thomas Fogarty, Patrick Maguire

  KEYWORDS: CyberHeart, Cardiac Radiosurgery, Atrial Fibrillation, Non-Invasive, Radiotherapy

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.6 No.5, May 27, 2016

  ABSTRACT: An estimated 4 million Americans currently have atrial fibrillation (AF), the most common form of cardiac arrhythmia. The annual growth rate of AF is approximately 9.2% and advanced statistical analyses project that the prevalence of AF will be 12.1 million in the United States by 2030. The current therapeutic options to treat AF put certain patient groups at a high risk for a serious bleeding event, stroke or thromboembolism, myocardial infarction, and death. The most effective treatment for AF—catheter ablation—has been widely reported to require repeat operations and only leaves 59.4% of patients AF-free after five years. A majority of the reported complications and increased risks for catheter ablation occur because the procedure is invasive. Thus, there is a need for a novel, non-invasive therapeutic option to treat AF that can potentially expand the treatable patient population, increase patient safety, and improve clinical outcomes. CyberHeart Inc. has been exploring the efficacy and potential of cardiac radiosurgery as an option to treat heart conditions such as AF. With its proprietary CardioPlanTM software, the CyberHeart System utilizes the Cyberknife stereotactic radiosurgery platform to non-invasively ablate the heart. Early studies have displayed that the CyberHeart System is highly accurate at delivering radiation to cardiac targets and effective at minimizing radiation exposure to healthy tissue that is in close proximity to the targeted anatomic region. The focus of this review is to present the current standard of treatment for AF, identify the specific patient population that is at a high risk for the current treatment modalities, and address the potential for the CyberHeart Stereotactic Radiosurgery System to noninvasively ablate cardiac tissue and return sinus rhythm to patients with AF.